ScripNovartis’s Cosentyx has amassed approvals for multiple dermatological and rheumatological conditions since its first green light in 2015 for psoriasis but a bid to add giant cell arteritis (GCA) to th
ScripCasualties Of Risk-Off My time in the City included the management of four UK-listed biotech investment trusts and unit trusts. Investment trusts date back to the mid-1800s and can invest in both priv
ScripBayer’s bid to maintain its lead in the anti-vascular endothelial growth factor (VEGF) eye disease space has received a boost with a fresh approval in Europe that extends the intervals between injecti
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Novartis Inks Four-Year Proteome Resear